DBV Technologies S.A. (DBVT)’s Financial Results Comparing With Alexion Pharmaceuticals Inc. (NASDAQ:ALXN)

Since DBV Technologies S.A. (NASDAQ:DBVT) and Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) are part of the Biotechnology industry, they are influenced by compare. The influences particularly affect the risk, analyst recommendations, profitability, institutional ownership, dividends, earnings and valuation of both companies.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
DBV Technologies S.A. 9 0.00 N/A -3.27 0.00
Alexion Pharmaceuticals Inc. 125 5.35 N/A 5.49 20.63

We can see in table 1 the earnings per share (EPS), top-line revenue and valuation of DBV Technologies S.A. and Alexion Pharmaceuticals Inc.


Table 2 hightlights the return on assets, net margins and return on equity of the two companies.

Net Margins Return on Equity Return on Assets
DBV Technologies S.A. 0.00% 0% 0%
Alexion Pharmaceuticals Inc. 0.00% 14% 9.5%

Analyst Ratings

DBV Technologies S.A. and Alexion Pharmaceuticals Inc. Ratings and Recommendations are available in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
DBV Technologies S.A. 0 0 1 3.00
Alexion Pharmaceuticals Inc. 0 0 4 3.00

$14 is DBV Technologies S.A.’s consensus price target while its potential upside is 36.59%. On the other hand, Alexion Pharmaceuticals Inc.’s potential upside is 48.98% and its consensus price target is $160. The data provided earlier shows that Alexion Pharmaceuticals Inc. appears more favorable than DBV Technologies S.A., based on analyst view.

Institutional and Insider Ownership

The shares of both DBV Technologies S.A. and Alexion Pharmaceuticals Inc. are owned by institutional investors at 46.27% and 98.8% respectively. Competitively, insiders own roughly 0.3% of Alexion Pharmaceuticals Inc.’s shares.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
DBV Technologies S.A. -6.24% 9.23% -0.94% 41.55% -46.5% 47.51%
Alexion Pharmaceuticals Inc. -6.35% -13.7% -15.54% -6.62% -13.85% 16.36%

For the past year DBV Technologies S.A. was more bullish than Alexion Pharmaceuticals Inc.


Alexion Pharmaceuticals Inc. beats DBV Technologies S.A. on 8 of the 9 factors.

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which is in Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults. The company is also developing Viaskin Milk that is in Phase II clinical trial for the treatment of Immunoglobulin E mediated cow’s milk protein allergy (CMPA) and milk-induced eosinophilic esophagitis; Viaskin Egg, a pre-clinical stage product for the treatment of hen’s egg allergy; and booster vaccine for Bordatella pertussis. Its other earlier stage product development programs include treatments for Crohn’s disease and respiratory syncytial virus. The company has collaboration with Nestlé Health Science to develop MAG1C, an atopy patch test for the diagnosis of CMPA in infants and toddlers. DBV Technologies S.A. was founded in 2002 and is headquartered in Montrouge, France.

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia (HPP); and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company conducts Phase III clinical trials for Soliris (eculizumab) for the treatment of myasthenia gravis and neuromyelitis optica spectrum disorder; and Phase II clinical trials for antibody mediated rejection in presensitized renal transplant patients. Further, it develops cPMP (ALXN 1101) that is in Phase II/III trial for treating metabolic disorders; SBC-103, which is in Phase I/II clinical trials for the treatment of metabolic disorders; ALXN 1210 (IV) that is in Phase III clinical trials for the treatment of PNH and aHUS; and ALXN 1210, which is in Phase I clinical trials to evaluate subcutaneous delivery. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other health care providers, as well as governments and government agencies in the United States, Europe, the Asia Pacific, and internationally. Alexion Pharmaceuticals, Inc. has agreements with X-Chem Pharmaceuticals (X-Chem) to identify novel drug candidates from X-Chem's proprietary drug discovery engine; and Moderna Therapeutics, Inc. (Moderna) that provides the option to purchase drug products for the development and commercialization of Moderna's messenger RNA therapeutics to treat rare diseases. The company was founded in 1992 and is headquartered in New Haven, Connecticut.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.